Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Vivoryon Therapeutics   /   Vivoryon is de naam. Daarom nieuw draadje

Aandeel VIVORYON THERAPEUTICS N.V. AEX:VVY.NL, NL00150002Q7

Laatste koers (eur) Verschil Volume
2,255   -0,045   (-1,96%) Dagrange 2,215 - 2,340 99.301   Gem. (3M) 177K

Vivoryon is de naam. Daarom nieuw draadje

Volgen
6.265 Posts
Pagina: «« 1 ... 245 246 247 248 249 ... 314 »» | Laatste | Omlaag ↓
  1. Kuiken 8 maart 2022 10:56
    Tja, waarom zou er in Amerika een tweede onderzoek lopen? Is al gedaan toch?
    Omdat iedere toezichthouder zo zijn eigen parameters hanteert.
    Omdat des te breder het onderzoek, des te veiliger een medicijn is .
    Omdat de diverse onderzoeken elkaars resultaten kunnen toetsen op dwaalwegen uitgefilterd worden en andersom
    er nieuwe inzichten aan kunnen worden toegevoegd.
    Dus: amerikanen verlenen : fast track,
    chinezen financieren,
    nu drie continenten die hier enige brood in zien!
  4. Kuiken 8 maart 2022 19:32
    bron Alzheimers News Today;
    let op het vetgedrukte.

    Gene Therapy LX1001 Showing Potential to Lower Tau Levels in Phase 1 Trial
    Patricia Inacio PhD
    by Patricia Inacio PhD | March 8, 2022




    LX1001, a one-time gene therapy for Alzheimer’s disease being developed by Lexeo Therapeutics, raised levels of the protective APOE2 protein in the cerebrospinal fluid (CSF), early data from an ongoing Phase 1/2 trial shows.

    Findings in a first patient group treated at low dose also showed the gene therapy reduced the levels of tau protein — a hallmark of Alzheimer’s. No serious adverse events have been reported, supporting the therapy’s safety.

    The Phase 1/2 trial (NCT03634007), underway in Florida and New York, aims to recruit 15 Alzheimer’s patients, 50 or older, with two copies of the APOE4 gene and mild cognitive impairment or mild to moderate dementia due to the disease.

    Eligible adults must also have abnormal amyloid protein deposits — called amyloid plaques — evident on brain scans and Alzheimer’s biomarkers in their cerebrospinal fluid, the liquid surrounding the brain and spinal cord. Contact information for those interested in learning more is available here.

    RECOMMENDED READING
    Latinos and Alzheimer's | Alzheimer's News Today | illustration of many hands meeting at center
    February 1, 2022 News by Steve Bryson PhD
    Aduhelm Phase 4 ENVISION Study to Increase Participant Diversity
    “Initial data have shown meaningful APOE2 target engagement and declines in cerebrospinal fluid biomarkers, which support our belief that LX1001 has therapeutic potential for APOE4-associated Alzheimer’s disease,” Jay A. Barth, MD, Lexeo’s executive vice president and chief medical officer, said in a press release.

    LX1001 uses a harmless viral vector to deliver a version of the APOE gene, called APOE2, to cells in the central nervous system (the brain and spinal cord).

    APOE2 is one of the three versions (alleles) of the APOE gene, the other two being APOE3 and APOE4. Every person inherits two copies of the APOE gene, one from each biological parent, and the combination received is associated with the risk of developing Alzheimer’s.

    Broadly, the APOE2 allele is associated with a lower Alzheimer’s risk while the APOE4 allele is linked to an increased risk.

    The open-label Phase 1/2 trial is testing three ascending doses — a low (5.0 x 1010 genome copies per mililiter, gc/ml), medium (1.6 x 10^11 gc/ml) and high dose (5.0 x 1011 gc/ml) — of LX1001 in patients with two APOE4 allele copies. Participants are assigned to one of these three dosing groups.

    Its main goals are to assess LX1001’s safety profile and determine a maximum-tolerated dose (the highest dose that can be given without unacceptable safety risks). Secondary goals include evaluating the gene therapy’s effects on the APOE protein.

    Data covering four patients in the low-dose group show that APOE2 protein levels in the CSF rose relative to the trial’s start (baseline measures). Two patients were followed for three months post-treatment and the other two for 12 months.

    Tau protein levels in the CSF — both total tau and phosphorylated tau or pTau — declined in the two people with 12 months of follow-up data. Alzheimer’s is characterized by the formation of tangles of tau protein in the brain, with pTau being particularly prone to forming aggregates. These atypical clumps are thought to be toxic to brain cells, driving disease progression.

    Early data from patients treated at medium dose and further findings in the low-dose group are expected by year’s end. Findings will be shared at a future medical conference.

    The gene therapy was granted fast track designation by the U.S. Food and Drug Administration (FDA) in May 2021. The designation gives Lexeo, as the therapy’s developer, access to more frequent meetings with the FDA to support and speed the therapy’s development and to expedite its review.

    “LX1001 is the lead program in our Alzheimer’s disease gene therapy portfolio. These encouraging data support our unique approach to target the genetics of Alzheimer’s disease with multiple gene therapy candidates,” said R. Nolan Townsend, CEO of Lexeo.

    “There is an urgent need for new treatments for this devastating condition, and we are extremely grateful to patients, their families and caregivers, as well as investigators who are participating in the trial,” Barth added.
  8. forum rang 4 SpecuKlaas 12 maart 2022 12:30
    Volgens mij geldt voor Vivo ook dit : ... " as the therapy’s developer, access to more frequent meetings with the FDA to support and speed the therapy’s development and to expedite its review. "

    Voor Vivo is deze FDA toegankelijkheid goed. Echter deze bovenstaande Developer is gewoon een concurrent voor Vivo. Voor Alzheimer zelf alleen maar goed meerdere onderzoekers.... daar gaat het feitelijk toch om, om een oplossing. Niet om mijn 'knikkers'
  18. Kuiken 14 maart 2022 17:19
    Dit is morgen: van VIVO's website:

    00
    DAYS
    06
    HOURS
    41
    MINUTES
    A NEW CHAPTER IN THE HISTORY OF AD/PD™
    AD/PD™ 2022? brings a new look and a new chapter in the history of the AD/PD™ series of conferences. By merging together with the AAT-AD/PD™ Advances in Alzheimer’s Therapies Focus Meeting, AD/PD™ is now transformed into an annual meeting, with a continuing focus on the ADVANCES IN SCIENCE & THERAPY of Alzheimer’s and Parkinson’s Diseases and related neurological disorders.
    We are excited to provide improved opportunities for international medical and scientific professionals to come together and discuss the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer’s, Parkinson’s and other related neurological disorders.
    A central theme of the 2022 conference will be to further advance innovative strategies in therapy and prevention, clinical trials and diagnostic markers, in order to focus on driving successful collaborations among academia and industry, leading to the development of innovative therapies and ultimately providing for a better future for patients and families affected by neurodegenerative diseases.
    AD/PD™ 2022 will be held as a hybrid conference, giving you the option to attend either virtually, or physically in Barcelona.
6.265 Posts
Pagina: «« 1 ... 245 246 247 248 249 ... 314 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

VIVORYON THERAPEUTICS N.V. Nieuws

  1. Vivoryon zoekt financiering voor nierstudie
  2. Medicijn Vivoryon verbetert nierfunctie bij diabetes
  3. Samenstelling AEX blijft ongewijzigd
  4. T&W kleiner in Vivoryon
  5. Slotcall: AEX komt met de schrik vrij en koers Vivoryon explodeert
  6. Slotcall: Wall Street helpt AEX aan nieuw slotrecord én weekwinst
  7. Vivoryon verlegt focus naar nierziekte
  8. Vivoryon stopt eerder met studie naar middel tegen Alzheimer
  9. Vivoryon publiceert cijfers 2023 eind april
  10. Warburgs vreselijke Vivoryon-misser